Search Login Register
infliximab
(Remicade)
Summary
Description:
a chimeric monoclonal antibody to TNFalpha for the treatment of Crohn's disease & rheumatoid arthritis
Also Known As:
Remicade; Centocor brand of infliximab; Essex brand of infliximab; MAb cA2; Schering brand of infliximab Show All >>
Networked: 5733
relevant articles (1132 outcomes,
959 trials/studies)
for this Drug
Key Diseases for which infliximab is
Relevant
-
Crohn Disease (Crohn's Disease)
:
363 outcomes 218 studies in 1562 results
-
Ulcerative Colitis
:
128 outcomes 103 studies in 574 results
-
Rheumatoid Arthritis
:
125 outcomes 195 studies in 1033 results
-
Psoriasis (Pustulosis Palmaris et Plantaris)
:
114 outcomes 93 studies in 568 results
-
Necrosis
:
75 outcomes 47 studies in 465 results
Show All >>
Drugs Related to infliximab
-
Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
-
adalimumab (Humira)
-
TNFR-Fc fusion protein (etanercept)
-
Methotrexate (Mexate)
-
infliximab (Remicade)
-
Azathioprine (Imuran)
-
Phenobarbital (Luminal)
-
Adrenal Cortex Hormones (Corticosteroids)
-
CDP870
-
Antibodies
Show All >>
Therapies Related to infliximab
-
Biological Therapy
-
Colectomy
-
Retreatment
-
Remission Induction
-
Aftercare (After-Treatment)
Show All >>
CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.